Ryan Newman

As VP of Operations at Avenge Bio, Inc., Ryan Newman is responsible for leading cross-functional teams to drive the development of IND-enabling programs, including lead candidate AVB-001. Prior to joining Avenge Bio, Inc. in 2020, Ryan held a number of roles across Business Development and Project Management with a focus on oncology and cell therapy. Most recently, Ryan was responsible for the operational management and organization of novel cell therapy programs at Sigilon Therapeutics where he led integrated project teams to deliver on key milestones from proof of concept program data through regulatory submissions and approvals (US and ex-US). Ryan is a graduate of the University of North Carolina at Chapel Hill, where he majored in Biology with a minor in Chemistry. He went on to earn an M.B.A. with a focus on Project Management from the Keller School of Management.